Recent outbreak activity and limited Phase 1 data for DNA and mRNA candidates underscore why traders assign only a 5.5% chance of a hantavirus vaccine reaching approval or broad availability by late 2026. Most candidates remain in preclinical or early human testing, with neutralizing antibody responses observed but multi-dose regimens and further efficacy trials required; standard regulatory pathways typically span several more years absent emergency acceleration. A 2026 Andes virus cluster has prompted modest additional funding and model studies in animal systems, yet no candidate has advanced to pivotal Phase 3 enrollment. New trial readouts or major government commitments could alter timelines, though historical precedent for orphan pathogens suggests limited near-term shifts.